scholarly journals Autologous Peripheral Blood Stem Cell Transplantation Improves Portal Hemodynamics in Patients with Hepatitis B Virus-related Decompensated Cirrhosis

2015 ◽  
Vol 15 (12) ◽  
Author(s):  
Qinzhi Deng ◽  
Ting Cai ◽  
Shun Zhang ◽  
Airong Hu ◽  
Xingfen Zhang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Stem Cell Transplantation ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Decompensated Cirrhosis ◽  
Portal Hemodynamics ◽  
B Virus ◽  
Blood Stem Cell Transplantation

Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation

2003 ◽  
Vol 17 (5) ◽  
pp. 438-443 ◽  
Author(s):  
Ramazan Idilman ◽  
Celalettin Üstün ◽  
Selim Karayalçın ◽  
Aslihan Aktemel ◽  
Ahmet R Turkyilmaz ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Virus Vaccination ◽  
B Virus ◽  
Blood Stem Cell Transplantation

Successful Reversion of Chronic Myelogenous Leukemia with Myelofibrosis by Allogeneic Peripheral Blood Stem Cell Transplantation.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5412-5412
Author(s):  
Ying Pang ◽  
Jiaye Hua ◽  
Ruizhen Chen ◽  
Ying Feng
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Platelet Count ◽  
Hepatitis B ◽  
Stem Cell Transplantation ◽  
Peripheral Blood ◽  
Blood Cells ◽  
Peripheral Blood Stem Cell ◽  
Myelogenous Leukemia ◽  
Blood Stem Cell Transplantation

Abstract Objective: To observe the effect of allogeneic peripheral blood stem cell transplantation (allo-PBSCT) on hematopoietic reconstitution of chronic myelogenous leukemia (CML) and reversion of myelofibrosis (MF). Methods: A 39 years old male patient diagnosed with CML complicated with MF and hepatitis B carrier condition (HBsAg+)underwent allo-PBSCT. The donor was the patient’s sibling, his 48 years old sister. Six loci on HLA-A, B, and DRB1 were completely matched with that of the recipient and HbsAb(+). Four days after the administration of G-CSF (250ug/day), PBSCs were collected from the donor for 3 consecutive days. A total volume of 168 ml was harvested. A median nucleated cell (MNC) count of 8.54 ×108/kg with 5.1 ×106 /kg of CD34+ cells were actually administered to the recipient. The conditioning regimen was busulfan/cyclophosphamide (BU/CY). The recipient was started on intravenous infusion (IV) of cyclosporine A (CSA) on Day -1 and a plasma concentration of 150–250 ng/L was maintained. IV methotrexate (MTX) 10mg/m2 was given on Days +1, +3, +6, and +11. Oral mycophenolate mofetil (MMF)was given from Days +1 to +28 for prophylaxis of acute graft-versus-host disease (GVHD). If the concentration of hemoglobin (Hb) decreased to less than 70 g/L and/or platelet count (BPC) less than 10×109 /L, the recipient was transfused with 60Co 25cGy irradiated and leuko-depleted red blood cells (RBCs) and/or single-donor platelets. Started from Day +3, the recipient was given G-CSF until white blood cells (WBC) increased to at least 3.0× 109 /L. EPO and Interleukin-11 were also given to stimulate the proliferation of the progenitors of erythrocytes and megakaryocytes. The recipient also received anisodamine with a 24 hour-maintenance dose to improve the microenvironment of hematopoiesis in bone marrow. Results: DNA-STR on Day +30 indicated a complete chimerism in the recipient. Bone marrow biopsy on Day +50 showed a dramatic decrease of myelofibrosis in the ground substance and active hematopoiesis. Reticulinfibers reduced to 1+. No significant change on splenomegaly was observed but the hepatitis B antigen had turned negative and HBsAb had appeared. Conclusion: 1. In order to prevent aggravation of MF, Allo-PBSCT needs to be considered as early as possible once the diagnosis of CML complicated with MF is made. 2. Transfusion with a large quantity of donor hematopoietic stem cells is beneficial for engraftment. 3. Strict Immunoinhibition of the recipient will decrease the incidence and degree of GVHD and improve engraftment. 4. The addition of agents which improve the microenvironment of hematopoiesis will enhance engraftment. 5. Recovery of the platelet count is promising post-transplantation whereas significant changes on splenomegaly was not observed. 6. Allo-PBSCT may be a promising therapy for hepatitis B.

Sign in / Sign up

Export Citation Format

Share Document